Imfinzi’s ADRIATIC Success Boosts AstraZeneca’s Lung Cancer Strategy
A win in limited-stage small cell lung cancer will contribute to the company’s larger ambition to treat half of all lung cancer patients by 2030.

A win in limited-stage small cell lung cancer will contribute to the company’s larger ambition to treat half of all lung cancer patients by 2030.